The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 214 results:
Author Title Type [ Year(Desc)]
Filters: Author is Liakopoulos, Vassilios  [Clear All Filters]
2023
Karava, V., Kondou A., Dotis J., Christoforidis A., Taparkou A., Farmaki E., et al. (2023).  Association between adipokine profile, systemic inflammation, muscle and protein energy wasting in children with chronic kidney disease.. J Ren Nutr.
Roumeliotis, S., Neofytou I. E., Maassen C., Lux P., Kantartzi K., Papachristou E., et al. (2023).  Association of Red Blood Cell Distribution Width and Neutrophil-to-Lymphocyte Ratio with Calcification and Cardiovascular Markers in Chronic Kidney Disease.. Metabolites. 13(2), 
Georgianos, P. I., Eleftheriadis T., & Liakopoulos V. (2023).  Combination therapy with an SGLT-2 inhibitor and finerenone in DKD: Are we there yet?. Eur J Clin Invest. 53(2), e13864.
Georgianos, P. I., Tziatzios G., Roumeliotis S., Vaios V., Sgouropoulou V., Tsalikakis D. G., et al. (2023).  Effect of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on cardiovascular outcomes in dialysis patients: a systematic review and meta-analysis.. Nephrol Dial Transplant. 38(1), 203-211.
Michou, V., Liakopoulos V., Roumeliotis S., Roumeliotis A., Anifanti M., Tsamos G., et al. (2023).  Effects of Home-Based Exercise Training on Cardiac Autonomic Neuropathy and Metabolic Profile in Diabetic Hemodialysis Patients.. Life (Basel). 13(1), 
Kourtidou, C., Rafailidis V., Varouktsi G., Kanakis E., Liakopoulos V., Vyzantiadis T-A., et al. (2023).  Effects of Sodium-Glucose Co-Transporter-2 Inhibitors on Markers of Vascular Damage.. J Pers Med. 13(3), 
Karakousis, N. D., Biliou S., Pyrgioti E. E., Georgakopoulos P. N., Liakopoulos V., & Papanas N. (2023).  Frailty, sarcopenia and diabetic kidney disease: where do we stand?. Int Urol Nephrol. 55(5), 1173-1181.
Hsiao, L-L., Shah K. M., Liew A., Abdellatif D., Balducci A., Haris Á., et al. (2023).  Kidney health for all: preparedness for the unexpected in supporting the vulnerable.. Kidney Int. 103(3), 436-443.
D'Arrigo, G., Gori M., Pitino A., Tsalikakis D. G., Liakopoulos V., Roumeliotis S., et al. (2023).  Measures of frequency and effect in clinical research.. Int Urol Nephrol.
Cepaityte, D., Leivaditis K., Varouktsi G., Roumeliotis A., Roumeliotis S., & Liakopoulos V. (2023).  N-Acetylcysteine: more than preventing contrast-induced nephropathy in uremic patients-focus on the antioxidant and anti-inflammatory properties.. Int Urol Nephrol. 55(6), 1481-1492.
Roumeliotis, S., Liakopoulos V., Veljkovic A., & Dounousi E. (2023).  Redox Systems Biology in Chronic Kidney Disease.. Oxid Med Cell Longev. 2023, 9864037.
Georgianos, P. I., Vaios V., Divani M., & Liakopoulos V. (2023).  Should we discontinue RAS-inhibitor therapy in patients with advanced CKD?. Expert Opin Pharmacother.
Georgianos, P. I., Vaios V., Eleftheriadis T., Papachristou E., & Liakopoulos V. (2023).  Therapeutic Advances in Diabetic Kidney Disease.. Int J Mol Sci. 24(3), 
Georgianos, P. I., Papachristou E., & Liakopoulos V. (2023).  Which blood pressure threshold indicates a therapeutic benefit for patients with chronic kidney disease?. Hypertens Res. 46(4), 890-892.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.